How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,691 results for

Gestational Diabetes Management

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. HbA1c point of care test for the diagnosis and management of diabetes mellitus

because these patients were included in the evidence presented for established diabetes, and suggested that the third item descriptor could be deleted. ESC noted that HbA1c testing is inappropriate for the diagnosis of gestational diabetes. ESC noted that consumers are likely to want access to an HbA1c PoC test if it helps them manage their condition better. ESC KEY ISSUES ESC ADVICE Coning Coning means that 34% of HbA1c tests are not reimbursed, but ESC was uncertain as to whether the correct (...) HbA1c point of care test for the diagnosis and management of diabetes mellitus 1 Public Summary Document Application No. 1431 – HbA1c point of care testing for the diagnosis and management of diabetes mellitus Applicant: Optum for IVD Australia Date of MSAC consideration: MSAC 70 th Meeting, 27 July 2017 Context for decision: MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC website 1. Purpose of application An application requesting three new Medicare Benefit

2017 Medical Services Advisory Committee

42. Mobile Health Applications for Self-Management of Diabetes

aspects of mHealth to examine in this review and to define the most important considerations for interpreting and applying evidence within the topic of this report. PICOTS Populations: We focused on non-pregnant adults with type 1 or type 2 diabetes, as KIs noted that both these groups are likely to use mobile health technologies in their self-management. We excluded children, adolescents, pregnant women with diabetes, and patients with gestational diabetes. Interventions (types of technologies): We (...) Mobile Health Applications for Self-Management of Diabetes e Technical Brief Number 31 Mobile Health Applications for Self-Management of DiabetesTechnical Brief Number 31 Mobile Applications for Self-Management of Diabetes Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract Nos. 290-2012-0004-C and -290-2017-0000-3C Prepared by: Scientific Resource Center Portland, OR Investigators

2018 Effective Health Care Program (AHRQ)

43. First aid Management of a Diabetic Emergency

First aid Management of a Diabetic Emergency ANZCOR Guideline 9.2.9 November 2017 Page 1 of 6 ANZCOR Guideline 9.2.9 – First aid Management of a Diabetic Emergency Summary Who does this guideline apply to? This guideline applies to adult and child victims. Who is the audience for this guideline? This guideline is for bystanders, first aiders and first aid providers. Recommendations The Australian and New Zealand Resuscitation Committee on Resuscitation (ANZCOR) make the following (...) with insulin. ‘Type 2 diabetes’ is more commonly recognised in adulthood, and requires a treatment combination of diet, exercise, medication, and sometimes insulin. Less commonly, ‘gestational diabetes’ may develop in pregnancy, and diabetes can also occur as a consequence of another disease or as a side effect of medication. Normally our body tightly controls its blood glucose level within a ‘normal’ range. Having diabetes negatively interferes with this control system, and people living with diabetes

2017 Australian Resuscitation Council

44. Reminder systems for women with previous gestational diabetes mellitus to increase uptake of testing for type 2 diabetes or impaired glucose tolerance. (Abstract)

Reminder systems for women with previous gestational diabetes mellitus to increase uptake of testing for type 2 diabetes or impaired glucose tolerance. The early postpartum period is an important time in which to identify the risk of diabetes in women with a history of gestational diabetes mellitus (GDM). Oral glucose tolerance and other tests can help guide lifestyle management and monitoring to reduce the future risk of type 2 diabetes mellitus.To assess whether reminder systems increase (...) the uptake of testing for type 2 diabetes or impaired glucose tolerance in women with a history of GDM.We searched MEDLINE and EMBASE (last searched 1 June 2013) and The Cochrane Library (last searched April 2013).We included randomised trials of women who had experienced GDM in the index pregnancy and who were then sent any modality of reminder (or control) to complete a test for type 2 diabetes after giving birth.Two authors independently screened titles and abstracts for relevance. One author

2014 Cochrane

45. Diabetes in pregnancy: management from preconception to the postnatal period

on diagnosing and treating gestational diabetes have been published. The landmark HAPO (Hyperglycemia and Adverse Pregnancy Outcomes) study resulted in consensus guidance on the definition of gestational diabetes that has been adopted by the World Health Organization and which would result in many more women being diagnosed with gestational diabetes. This has Diabetes in pregnancy: management from preconception to the postnatal period (NG3) © NICE 2019. All rights reserved. Subject to Notice of rights (...) Diabetes in pregnancy: management from preconception to the postnatal period Diabetes in pregnancy: management Diabetes in pregnancy: management from preconception to the postnatal from preconception to the postnatal period period NICE guideline Published: 25 February 2015 nice.org.uk/guidance/ng3 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations

2015 National Institute for Health and Clinical Excellence - Clinical Guidelines

46. Using technology to support care in gestational diabetes mellitus: Quantitative outcomes of an exploratory randomised control trial of adjunct telemedicine for gestational diabetes mellitus (TeleGDM). (Abstract)

Using technology to support care in gestational diabetes mellitus: Quantitative outcomes of an exploratory randomised control trial of adjunct telemedicine for gestational diabetes mellitus (TeleGDM). The increasing incidence and prevalence of gestational diabetes mellitus (GDM) on a background of limited resources calls for innovative approaches healthcare provision. Our aim was to explore the effects of telemedicine supported GDM care on a range of health service utilisation and maternal (...) and foetal outcomes.An exploratory randomised controlled trial of adjunct telemedicine support in the management of insulin-treated GDM compared to usual care control. Outcomes included health service use, maternal and foetal clinical outcomes as well as costs. Groups were compared on outcomes and Poisson and Cox regression analysis were performed for predictors of health service utilisation, glycaemic control and costs.95 participants were recruited (intervention n = 61, control n = 34). There were

2018 Diabetes research and clinical practice Controlled trial quality: uncertain

47. Experiences of gestational diabetes and gestational diabetes care: a focus group and interview study. Full Text available with Trip Pro

Experiences of gestational diabetes and gestational diabetes care: a focus group and interview study. Gestational diabetes mellitus (GDM) is an increasingly common condition of pregnancy. It is associated with adverse fetal, infant and maternal outcomes, as well as an increased risk of GDM in future pregnancies and type 2 diabetes for both mother and offspring. Previous studies have shown that GDM can result in an emotionally distressing pregnancy, but there is little research on the patient (...) experience of GDM care, especially of a demographically diverse UK population. The aim of this research was to explore the experiences of GDM and GDM care for a group of women attending a large diabetes pregnancy unit in southeast London, UK, in order to improve care.Framework analysis was used to support an integrated analysis of data from six focus groups with 35 women and semi-structured interviews with 15 women, held in 2015. Participants were purposively sampled and were representative

2018 BMC Pregnancy and Childbirth

48. Randomized clinical trial: Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus

Randomized clinical trial: Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see (...) our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus Article

2016 Evidence-Based Medicine

49. Immediate delivery or expectant management in gestational diabetes at term: the GINEXMAL randomised controlled trial Full Text available with Trip Pro

Immediate delivery or expectant management in gestational diabetes at term: the GINEXMAL randomised controlled trial To evaluate maternal and perinatal outcomes after induction of labour versus expectant management in pregnant women with gestational diabetes at term.Multicentre open-label randomised controlled trial.Eight teaching hospitals in Italy, Slovenia, and Israel.Singleton pregnancy, diagnosed with gestational diabetes by the International Association of Diabetes and Pregnancy Study (...) diabetes, without other maternal or fetal conditions, no difference was detected in birth outcomes regardless of the approach used (i.e. active versus expectant management). Although the study was underpowered, the magnitude of the between-group difference was very small and without clinical relevance.Immediate delivery or expectant management in gestational diabetes at term?© 2016 Royal College of Obstetricians and Gynaecologists.

2016 EvidenceUpdates

50. Continuous glucose monitoring results in lower HbA1c in Malaysian women with insulin-treated gestational diabetes: a randomized controlled trial Full Text available with Trip Pro

and 36 weeks' gestation (Group 1, CGM, n = 25) or usual antenatal care without CGM (Group 2, control, n = 25). All women performed seven-point capillary blood glucose (CBG) profiles at least 3 days per week and recorded hypoglycaemic events (symptomatic and asymptomatic CBG < 3.5 mmol/l; non-fasting < 4.0 mmol/l). HbA1c was measured at 28, 33 and 37 weeks. In Group 1, both CGM and CBG data were used to manage diabetes, whereas mothers in Group 2 were managed based on CBG data alone.Baseline (...) Continuous glucose monitoring results in lower HbA1c in Malaysian women with insulin-treated gestational diabetes: a randomized controlled trial To determine if therapeutic, retrospective continuous glucose monitoring (CGM) improves HbA1c with less hypoglycaemia in women with insulin-treated gestational diabetes mellitus (GDM).This prospective, randomized controlled, open-label trial evaluated 50 women with insulin-treated GDM randomized to either retrospective CGM (6-day sensor) at 28, 32

2018 EvidenceUpdates

51. The cost-effectiveness of gestational diabetes screening including prevention of type 2 diabetes: application of a new model in India and Israel Full Text available with Trip Pro

or lifestyle management, or both for diabetes, and antenatal interventions for perinatal adverse events. The comparator was no gestational diabetes screening. Location/setting India and Israel/secondary care. Methods Analytical approach: A published decision analysis model was used to assess the cost-effectiveness of the intervention for a cohort of 1,000 women, in two settings with contrasting epidemiology and costs. For India, a general medical facility was considered, and for Israel, a large health (...) The cost-effectiveness of gestational diabetes screening including prevention of type 2 diabetes: application of a new model in India and Israel The cost-effectiveness of gestational diabetes screening including prevention of type 2 diabetes: application of a new model in India and Israel The cost-effectiveness of gestational diabetes screening including prevention of type 2 diabetes: application of a new model in India and Israel Marseille E, Lohse N, Jiwani A, Hod M, Seshiah V, Yajnik CS

2014 NHS Economic Evaluation Database.

52. The role of education in the management of gestational diabetes: a systematic review

The role of education in the management of gestational diabetes: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing (...) models Example: Heterogeneity will be assessed using the (residual) I2 and adjusted R2 statistics. ">Heterogeneity For further guidance please refer to the and to pre-clinical meta-analysis. Example: Whenever a control group serves more than one experimental group, we will correct the total number of control animals in the meta-analysis by dividing the number of animals in the control group by the number of treatment groups served. Where applicable, Holm-Bonferroni correction for testing multiple

2018 PROSPERO

53. Gestational Diabetes Insulin Management Intrapartum

Gestational Diabetes Insulin Management Intrapartum Gestational Diabetes Insulin Management Intrapartum Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer (...) Administration 4 Gestational Diabetes Insulin Management Intrapartum Gestational Diabetes Insulin Management Intrapartum Aka: Gestational Diabetes Insulin Management Intrapartum , Insulin Management in Labor II. Indication in Labor Diet controlled rarely warrants intrapartum management III. Preparation Patient Use only 50% of long acting (e.g. / or / ) on the day of delivery Dilute 25 units Regular in 250 cc Coadminister maintenance fluids at 125 cc/hour IV. Monitoring Intrapartum Fingerstick every 1 to 2

2018 FP Notebook

54. Gestational Diabetes Insulin Management

Gestational Diabetes Insulin Management Gestational Diabetes Insulin Management Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 (...) Gestational Diabetes Insulin Management Gestational Diabetes Insulin Management Aka: Gestational Diabetes Insulin Management , Insulin Management in Pregnancy II. Indication Failed Gastational Diabetes Diet Management III. Protocol: Calculate Ideal Body Weight Start with 100 pounds + 5 pounds per inch over 5 feet Add 30 pounds for pregnancy Convert to Kilograms: Pounds / 2.2 IV. Protocol: Calculate Total Daily Calories Option 1 Calories/day = (in kg) x 35 KCal/kg Option 2 (if BMI > 30 kg/m2) Calories/day

2018 FP Notebook

55. Gestational Diabetes Management

Gestational Diabetes Management Gestational Diabetes Management Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Gestational Diabetes (...) Management Gestational Diabetes Management Aka: Gestational Diabetes Management II. Indications: Gestational Diabetes Abnormal Preexisting III. Monitoring: Blood Glucose Frequency of therapy 4 times daily Diet control s 4 times on 2 days per week Increase monitoring if 2 values/week abnormal Target Levels Before Breakfast or early morning (2-6 am): 60 to 95 mg/dl Before Lunch,Dinner: 60 to 115 mg/dl One hour post prandial goal: under 140 mg/dl Two hour post prandial goal: under 120 mg/dl Check s in early

2018 FP Notebook

56. Management of glycaemic control in pregnant women with diabetes on obstetric wards and delivery units

/joint-british-diabetes-society We are eager to find out about your experiences using this guideline, particularly any data from audits of its use in situ. This will be used in the next update of the guideline. Please contact Dr Umesh Dashora u.dashora@nhs.net3 Scope of the guideline This guideline provides guidance on the management of women with pre-existing diabetes (type 1 or type 2), or gestational diabetes when admitted to maternity units in the following situations: • Induction of labour (...) PRESCRIPTION OF INTRAVENOUS MANAGEMENT OF HYPOGLYCAEMIA Date Time Preparation Volume Route Duration Prescriber’s signature Print name Given by: Time given: 20% Dextrose 100ml IV 15 min CAPILLARY BLOOD GLUCOSE MONITORING GESTATIONAL DIABETES: STOP VRIII and IV Substrate Fluid regime once placenta is delivered Date 01:00 02:00 03:00 04:00 05:00 06:00 07:00 08:00 09:00 10:00 11:00 12:00 CBG Insulin rate Blood ketones TYPE 1 DM and INSULIN TREATED TYPE 2 DM Reduce the rate of VRIII by HALF once placenta

2017 Association of British Clinical Diabetologists

57. Integrated sensor-augmented pump therapy systems for managing blood glucose levels in type 1 diabetes (the MiniMed Paradigm Veo system and the Vibe and G4 PLATINUM CGM system)

in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Integrated sensor-augmented pump therapy systems for managing blood glucose levels in type 1 diabetes (the MiniMed Paradigm Veo system and the Vibe and G4 PLATINUM CGM system (...) diabetes (the MiniMed Paradigm Veo system and the Vibe and G4 PLATINUM CGM system) (DG21) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 5011 Sources of evidence considered by the Committee 46 Registered stakeholders 46 Glossary 48 Disabling hypoglycaemia 48 About this guidance 49 Integrated sensor-augmented pump therapy systems for managing blood glucose levels in type 1 diabetes (the MiniMed Paradigm Veo system

2016 National Institute for Health and Clinical Excellence - Diagnostics Guidance

58. Management of Diabetes Mellitus in Primary Care

. The insulin resistance resulting in T2DM is thought to be due to excess adiposity, especially central distribution of adiposity, but can be due to other factors, such as corticosteroid treatment or Cushing’s syndrome. Gestational diabetes (GDM) is DM present during pregnancy. Other more unusual types of DM also exist, such as maturity onset diabetes of the young (MODY), latent VA/DoD Clinical Practice Guideline for the Management of Type 2 Diabetes Mellitus in Primary Care April 2017 Page 6 of 160 (...) of clinical practice guidelines for the VA and DoD populations.[1] This clinical practice guideline (CPG) is intended to provide healthcare providers with a framework by which to evaluate, treat, and manage the individual needs and preferences of patients with diabetes mellitus (DM), thereby leading to improved clinical outcomes. The first VA/DoD CPG for the Management of Diabetes Mellitus, based upon earlier iterations in 1997 and 2000, was published in 2003.[2] It established a risk stratification

2017 VA/DoD Clinical Practice Guidelines

59. Improving outcomes in gestational diabetes: does gestational weight gain matter? Full Text available with Trip Pro

Improving outcomes in gestational diabetes: does gestational weight gain matter? Excessive gestational weight gain increases risk of gestational diabetes mellitus (GDM) but it remains unclear whether weight control after GDM diagnosis improves outcomes. We assessed whether: (1) total gestational weight gain during pregnancy (0-36 weeks); (2) early gestational weight gain (0-28 weeks, before GDM diagnosis); or (3) late gestational weight gain (28-36 weeks, after diagnosis) are associated (...) with women with substantial weight gain after diagnosis. There were no significant associations between early gestational weight gain (0-28 weeks) and pregnancy outcomes.These findings suggest that controlling gestational weight gain should be a priority following GDM diagnosis to optimize pregnancy outcomes and improve maternal postnatal glucose homeostasis. The period after diagnosis of GDM (often 28 weeks gestation) is not too late to offer lifestyle advice or intervention to improve weight management

2018 Diabetic Medicine

60. A comparison of changes in gestational weight, body mass index and serum vitamin D level in gestational diabetes mellitus patients complemented with vitamin D contrasted to those who did not receive the supplement: a protocol for systematic review and met

A comparison of changes in gestational weight, body mass index and serum vitamin D level in gestational diabetes mellitus patients complemented with vitamin D contrasted to those who did not receive the supplement: a protocol for systematic review and met Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied (...) ) variance. Should the excessive between-study variance be very low or zero, the random-effects model will yield the same results as the fixed-effect model. For further details, see the and to pre-clinical meta-analysis. Example: Because of the exploratory nature of animal studies, a random effects model will be used to account for anticipated heterogeneity. ">Effect models Example: Heterogeneity will be assessed using the (residual) I2 and adjusted R2 statistics. ">Heterogeneity For further guidance

2020 PROSPERO

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>